Full-Time

Associate Director / Director

Alliance Management

Confirmed live in the last 24 hours

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

No salary listed

Senior

Burlingame, CA, USA + 1 more

More locations: San Diego, CA, USA

Hybrid schedule; candidates may work from either Burlingame or San Diego offices.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Machine Learning
PowerPoint/Keynote/Slides
Requirements
  • PhD in chemistry, life sciences, machine learning, or similar computational field, with focus on drug discovery applications
  • 6-8+ years of industrial experience across biotech / pharmaceutical operating roles, and/or life sciences consulting roles serving major pharmaceutical companies
  • Experience operating in a fast-paced environment at the intersection of science and business (e.g., top-tier strategy consulting, venture-backed biotech startups)
  • Deep expertise in preclinical small molecule drug discovery (e.g., medicinal chemistry at a major pharmaceutical company, or similar exposure to molecular drug design)
  • Strong project management experience involving cross-functional scientific teams
  • Ability to travel domestically and internationally, if required, approximately 10% time
  • Excellent Powerpoint, presentation, Excel modeling, communication and listening skills
Responsibilities
  • Act as alliance manager for Genesis’s AI-focused research collaborations with major pharmaceutical companies
  • Own communication with key external stakeholders, support Genesis project teams, and drive preparations for all joint research governance meetings
  • Act as business lead on critical technology and AI infrastructure deals to support GEMS platform capabilities and leading computational research at Genesis
  • Support Genesis corporate communications and media strategy, interfacing directly with Genesis’s external communications agency
  • Provide strategic perspectives on GEMS platform roadmap based on insights from partnerships with major pharmaceutical and technology companies
Desired Qualifications
  • Alliance management within a fast-paced biotech company, or similar external-facing roles, particularly if involved in discovery collaborations with top pharma partners
  • Complex transactions and licensing contracts in life sciences and technology
  • Emerging AI technologies and other computational screening tools for discovery of small molecule drug candidates
  • AI technology landscape, including cloud computing and technology infrastructure providers
  • Financial and budgetary analysis of strategic alliances for corporate decision making and long-range planning
  • Corporate communications in life sciences / technology

Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis focuses on strategic partnerships with other biotech and pharmaceutical companies, exemplified by a deal with Eli Lilly. The goal is to discover critical new medicines through advanced technology and collaboration.

Company Size

51-200

Company Stage

Series B

Total Funding

$280.1M

Headquarters

Burlingame, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with NVIDIA enhances AI capabilities for drug discovery.
  • Strategic collaborations expand therapeutic pipeline and address unmet medical needs.
  • Recognition as a 'Fierce 15' company boosts industry credibility.

What critics are saying

  • High competition from AI-driven drug discovery companies like Insilico Medicine.
  • Over-reliance on partnerships could lead to financial instability.
  • Rapid AI advancements may render current models obsolete without continuous innovation.

What makes Genesis Therapeutics unique

  • Genesis uses 3D spatial graph modeling for novel drug candidate generation.
  • The GEMS platform leverages physics-inspired AI for drug discovery.
  • Genesis collaborates with major pharma companies like Eli Lilly and Gilead.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

3%
Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.

Genetic Engineering & Biotechnology News
Dec 18th, 2024
Genesis Therapeutics Secures Nvidia Investment Boost

Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.

Finsmes
Nov 14th, 2024
Genesis Therapeutics Receives Equity Investment From NVIDIA

Genesis Therapeutics receives equity investment from NVIDIA.

BioPharmaTrend
Nov 13th, 2024
Genesis Therapeutics, NVIDIA Partner; $200M Boost

Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.

ProHost Biotech
Sep 10th, 2024
Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.